Jean M. Franchi, Chief Financial Officer of Disc Medicine (NASDAQ: IRON), sold a total of 6,657 shares of the company's common stock in two transactions executed on April 13 and April 14, 2026, producing proceeds of approximately $460,834.
The first transaction took place on April 13 and involved 400 shares at $69.00 per share. The larger block, executed on April 14, consisted of 6,257 shares sold at a weighted average price of $69.2399. Those April 14 sales were carried out in multiple trades at prices ranging from $69.07 to $69.43, inclusive. After these dispositions, Franchi's direct ownership in Disc Medicine stands at 64,333 shares.
The sales were made under a pre-established Rule 10b5-1 trading plan that Franchi adopted on September 25, 2025. The company's stock is quoted at $70.18 at the time of reporting, a level that represents a 71% gain over the last 12 months. According to InvestingPro analysis referenced by the company, IRON appears overvalued at current levels; that service also offers 11 additional tips for IRON and a Pro Research Report described as a way to convert complex data into actionable intelligence.
Disc Medicine recently reported progress on its clinical and corporate fronts. The company said it has completed enrollment in its Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP). Enrollment for the trial was expanded to 183 participants to meet demand, and the company noted enrollment finished in under a year.
At the same time, Disc Medicine disclosed that it has begun a workforce reduction and broader restructuring following receipt of a Complete Response Letter from the U.S. Food and Drug Administration regarding the company's New Drug Application for bitopertin. The plan is expected to reduce headcount by roughly 20% and to be substantially complete in the second quarter of 2026.
Market analysts reacted to the FDA correspondence with revised targets and ratings. Stifel reiterated a Buy rating on Disc Medicine but lowered its price target from $125 to $110 in light of the regulatory response. Cantor Fitzgerald maintained an Overweight rating while reducing its price target from $153 to $125. Stifel's evaluation also incorporated recently released data from a competing drug trial, which reportedly showed a smaller effect size for the rival treatment.
These moves - the insider stock sales executed under a 10b5-1 plan, the completion of a larger-than-expected Phase 3 enrollment, the regulatory setback leading to workforce reductions, and the analyst adjustments - together underscore the complex position Disc Medicine occupies as it advances clinical development while responding to regulatory and operational pressures.